<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886262</url>
  </required_header>
  <id_info>
    <org_study_id>Vasopressin HR #17345</org_study_id>
    <nct_id>NCT00886262</nct_id>
  </id_info>
  <brief_title>Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant</brief_title>
  <official_title>Low Dose Vasopressin for Renal Protection During Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate the medication vasopressin for its ability to preserve
      kidney function in patients undergoing liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Renal failure is a common complication of liver disease. Hepatorenal syndrome is caused by a
      dysfunctional global circulation in the setting of liver disease: Increased flow to the
      mesenteric circulation is a contributor to decreased blood flow to the kidneys (1). Renal
      failure often worsens in the perioperative period of liver transplantation since the kidneys
      are further stressed by reduced flow due to inferior venacava occlusion, decreased blood flow
      to the kidneys from anesthetics, as well as hypotension from volume shifts, such as when
      large volumes of ascites are removed. Renal failure is a cause of major morbidity and
      mortality in patients undergoing liver transplantation.

      Vasopressin is a logical choice of therapy in this context as the effects of the drug work to
      particularly increase renal blood flow and glomerular filtration rate due to the location of
      specific vasopressin receptors within the renal vasculature. It has been suggested that the
      use of splanchnic (and systemic) vasoconstrictors such as terlipressin (a vasopressin analog)
      or alpha-1-adrenoceptor agonists (midodrine or noradrenaline) may improve renal function in
      patients with type 1 Hepatorenal Syndrome.

      Six studies (with only one randomized study in a small series of patients) have shown that
      terlipressin improves renal function in these patients (2-7). This drug is available in
      Europe, but not in the United States. However, while anesthesiologists commonly use
      vasopressin during liver transplantation in the setting of hepatorenal syndrome or
      vasodilatory shock, the validity of this practice for its effects on renal function and
      outcomes has not been rigorously studied (8-10). Therefore, the purpose of this study is to
      evaluate the effects of low-dose vasopressin on intraoperative and perioperative renal
      function in liver transplant patients.

      This study will be a randomized, double-blind controlled trial performed in adult liver
      transplant patients coming to surgery for chronic liver disease; the major end-points of
      analyses are renal function tests in the perioperative period.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low dose vasopressin given during liver transplantation prevents renal dysfunction in the perioperative period confirmed by evaluating creatinine postoperatively.</measure>
    <time_frame>baseline, 24 hours postop, 48 hours postop</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Low dose vasopressin given during liver transplantation prevents renal dysfunction in the perioperative period confirmed by evaluating urine output postoperatively</measure>
    <time_frame>baseline, 24 hours postop, 48 hours postop</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low-dose vasopressin given during liver transplantation prevents renal dysfunction in the perioperative period confirmed by evaluating the need for diuretics in the perioperative period.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-dose Vasopressin given during liver transplantation prevents renal dysfunction in the perioperative period confirmed by evaluating hemodynamic stability/requirement of additional vasopressors in the perioperative period.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>Vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed</description>
    <arm_group_label>Vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline placebo</intervention_name>
    <description>Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter</description>
    <arm_group_label>Normal saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age

          -  undergoing liver transplant

          -  ability to provide informed consent. If patient is unable to give informed consent
             i.e. hepatic encephalopathy, consent may be obtained from the patient's legally
             authorized representative

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew D McEvoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology. 2006 Mar;43(3):385-94. Review.</citation>
    <PMID>16496352</PMID>
  </reference>
  <reference>
    <citation>Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000 Jul;33(1):43-8.</citation>
    <PMID>10905585</PMID>
  </reference>
  <reference>
    <citation>Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg. 2001 Jan-Mar;64(1):15-9.</citation>
    <PMID>11322061</PMID>
  </reference>
  <reference>
    <citation>Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002 Apr;122(4):923-30.</citation>
    <PMID>11910344</PMID>
  </reference>
  <reference>
    <citation>Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8.</citation>
    <PMID>11981339</PMID>
  </reference>
  <reference>
    <citation>Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002 Oct;36(4 Pt 1):941-8.</citation>
    <PMID>12297842</PMID>
  </reference>
  <reference>
    <citation>Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003 Feb;18(2):152-6.</citation>
    <PMID>12542598</PMID>
  </reference>
  <reference>
    <citation>Csete M. IARS 2007 Review Course Lectures: Anesthesia for Liver Transplantation. Anes Analg 2007; 104:19-24,2007.</citation>
  </reference>
  <reference>
    <citation>Roth JV. The use of vasopressin bolus to treat refractory hypotension secondary to reperfusion during orthotopic liver transplantation. Anesth Analg. 2006 Jul;103(1):261.</citation>
    <PMID>16790680</PMID>
  </reference>
  <reference>
    <citation>De Wolf AM. Preoperative optimization of patients with liver disease. Curr Opin Anaesthesiol. 2005 Jun;18(3):325-31.</citation>
    <PMID>16534358</PMID>
  </reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>April 21, 2009</last_update_submitted>
  <last_update_submitted_qc>April 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Matthew D. McEvoy MD</name_title>
    <organization>Medical University of South Carolina</organization>
  </responsible_party>
  <keyword>liver transplantation</keyword>
  <keyword>vasopressin</keyword>
  <keyword>renal function</keyword>
  <keyword>hypotension</keyword>
  <keyword>creatinine</keyword>
  <keyword>urine output</keyword>
  <keyword>diuretics</keyword>
  <keyword>vasopressors</keyword>
  <keyword>hemodynamic stability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

